Invesco Nasdaq Biotechnology ETF
IBBQ
NASDAQ Global Market- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund that seeks to track the performance of the Nasdaq Biotechnology Index, a modified market-cap-weighted index comprising biotechnology and pharmaceutical companies listed on the Nasdaq stock exchange. The fund normally invests at least 90% of its total assets in securities that comprise the index, providing investors with exposure to approximately 260 holdings, including top positions such as Gilead Sciences Inc. (7-8%), Amgen Inc. (7%), Regeneron Pharmaceuticals Inc. (6-7%), Vertex Pharmaceuticals Inc. (6-7%), and AstraZeneca PLC (4-5%); other notable holdings encompass Alnylam Pharmaceuticals Inc., Insmed Inc., argenx SE, Biogen Inc., and emerging names like Tempus AI Inc. Launched on June 11, 2021, IBBQ features a low net expense ratio of 0.19%, quarterly dividend distributions (most recent ex-dividend June 23, 2025, at $0.0287 per share), and operates primarily in the health care sector with a focus on U.S.-listed equities (88% U.S. stocks, 12% non-U.S. stocks). IBBQ is issued and managed by Invesco Ltd., a global investment management firm founded in 1935 and headquartered in Atlanta, Georgia, with operations across more than 20 countries and over $1.5 trillion in assets under management as of late 2023. Invesco provides a broad array of investment products, including ETFs under brands like PowerShares, alongside active, passive, and alternative strategies targeting institutional and retail investors worldwide. Recent developments for IBBQ include ongoing index reconstitutions by Nasdaq, which in prior years added record numbers of new small-cap biotech components via IPOs, enhancing the fund's exposure to innovative growth areas. While IBBQ itself has seen no major structural changes, issuer Invesco has pursued strategic expansions in 2025, such as launching the Invesco Galaxy Solana ETP (QSOL) on December 15 through its partnership with Galaxy Digital to broaden digital assets access, alongside new thematic ETFs like the SteelPath MLP & Energy Infrastructure ETF (PIPE) in February. Invesco also reported strong net long-term inflows of nearly $29 billion in Q3 2025, reflecting robust growth in its ETF lineup amid market shifts toward passive and alternative investments.